Ventas Inc (VTR)
Official siteREAL ESTATE • REIT - HEALTHCARE FACILITIES • NYSE
Market Cap: $47.02B
Last updated: Nov 17, 2026 at 11:05 AM ET
Ventas Inc (VTR) P/E Ratio & Valuation History
Ventas (VTR) trades at 20.7x its 2026 FFO estimate. Its forward P/E is 131.6x. It trades at 6.8x sales and 3.0x book value. Its P/S is above its 5-year median of 6.4x.
Current Multiples
Its P/FFO of 20.7x uses the 2026 FFO estimate of $4.30 per share. Its enterprise value is 32.3x its EBITDA.
| Multiple | Value |
|---|---|
| P/FFO (2026 estimate) | 20.7x |
| P/E (trailing) | 40.6x |
| Forward P/E | 131.6x |
| Price to sales | 6.8x |
| Price to book | 3.0x |
| EV/EBITDA | 32.3x |
| PEG | 5.1 |
Historical Medians
Against its 10-year medians, its P/S is 7.9% above 6.3x and its P/B is 30.4% above 2.3x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 6.8x | 6.4x | 6.3x |
| P/B | 3.0x | 2.7x | 2.3x |
Valuation History
Over the 7 of the 10 year ends shown that have a P/E, its P/E ranged from 25.1x in 2017 to 346.4x in 2024.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $77.38 | 154.8x | 6.0x | 3.0x |
| 2024 | $58.89 | 346.4x | 7.9x | 2.3x |
| 2023 | $49.84 | N/A | 6.0x | 2.1x |
| 2022 | $45.05 | N/A | 4.9x | 1.8x |
| 2021 | $51.12 | N/A | 10.0x | 1.9x |
| 2020 | $49.04 | 76.6x | 7.5x | 1.8x |
| 2019 | $57.74 | 50.6x | 5.5x | 2.1x |
| 2018 | $58.59 | 58.6x | 5.6x | 2.1x |
| 2017 | $60.01 | 25.1x | 6.0x | 2.0x |
| 2016 | $62.52 | 33.6x | 6.3x | 2.1x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VTR
What is VTR's forward P/E ratio?
Ventas has a forward P/E ratio of 131.6x. It trades at 20.7x its 2026 FFO estimate.
Is VTR stock overvalued?
Ventas trades at 20.7x its 2026 FFO estimate. GNG's valuation label for VTR is Fairly valued.
What is VTR's price to sales ratio?
Ventas has a price to sales ratio of 6.8x.
What is VTR's PEG ratio?
Ventas has a PEG ratio of 5.1.
VTR pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors